Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Lake Forest, Ill, Jan. 06, 2023 (GLOBE NEWSWIRE)

Company

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that as of January 3, 2023, the Compensation Committee of the Company’s Board of Directors granted four newly-hired employees a total of 14,804 restricted stock units (“RSUs”).

These inducement grants were made under the NASDAQ Listing Rule 5635(c)(4), which allows for the issuance of RSUs to individuals newly employed by the Company as an inducement material to such individuals entering into employment with the Company.

Assertio focuses on providing innovative products to meet the needs of patients and healthcare providers. The Company is committed to delivering quality solutions that make a difference in people’s lives.

Impact on Individuals

For individuals who have been granted RSUs, this news is significant as it represents a tangible commitment from the Company towards their future with Assertio. RSUs are a valuable form of compensation that can align employees’ interests with the long-term success of the Company.

By receiving RSUs, these employees have the opportunity to benefit from the growth and performance of Assertio, encouraging them to contribute to the Company’s success and share in the rewards.

Impact on the World

While the inducement grants may seem like a small internal matter, they reflect the larger impact of Assertio Holdings, Inc. on the pharmaceutical industry and ultimately on patient care. By attracting top talent with competitive compensation packages, Assertio can continue to develop and deliver innovative products that improve the quality of life for patients.

As Assertio grows and succeeds, it has the potential to positively influence the healthcare landscape by offering new treatment options and generating advancements in medical technology. This ripple effect can benefit not only individuals directly involved with the Company but also patients and healthcare providers around the world.

Conclusion

Assertio Holdings, Inc.’s inducement grants under NASDAQ Listing Rule 5635(c)(4) demonstrate the Company’s commitment to attracting and retaining top talent to drive innovation and growth. These grants not only offer valuable compensation opportunities to individuals but also have the potential to impact the broader pharmaceutical industry and patient care worldwide.